Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity

Abstract excerpt

Doxorubicin is an important anticancer drug in the clinic. Unfortunately, it causes cumulative and dose-dependent cardiotoxic side effects. As the population of cancer survivors who have been exposed to treatment continues to grow, there is increased interest in assessing the long-term cardiac effects of doxorubicin and understanding the underlying mechanisms at play. In this study, we investigated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related cognitive impairment studies
• Share to Chemotherapy-induced cardiotoxicity and mitigation
• Share to Neuroblastoma Research and Treatments